PROX1 and beta-catenin are prognostic markers in pancreatic ductal adenocarcinoma

Show full item record



Permalink

http://hdl.handle.net/10138/165967

Citation

Saukkonen , K , Hagstrom , J , Mustonen , H , Juuti , A , Nordling , S , Kallio , P , Alitalo , K , Seppanen , H & Haglund , C 2016 , ' PROX1 and beta-catenin are prognostic markers in pancreatic ductal adenocarcinoma ' , BMC Cancer , vol. 16 , 472 . https://doi.org/10.1186/s12885-016-2497-5

Title: PROX1 and beta-catenin are prognostic markers in pancreatic ductal adenocarcinoma
Author: Saukkonen, Kapo; Hagstrom, Jaana; Mustonen, Harri; Juuti, Anne; Nordling, Stig; Kallio, Pauliina; Alitalo, Kari; Seppanen, Hanna; Haglund, Caj
Contributor: University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, II kirurgian klinikka
University of Helsinki, Medicum
University of Helsinki, Research Programs Unit
University of Helsinki, Research Programs Unit
University of Helsinki, Clinicum
University of Helsinki, Clinicum
Date: 2016-07-13
Language: eng
Number of pages: 12
Belongs to series: BMC Cancer
ISSN: 1471-2407
URI: http://hdl.handle.net/10138/165967
Abstract: Background: The Wnt/beta-catenin pathway has a key role in regulating cellular processes and its aberrant signaling can lead to cancer development. The role of beta-catenin expression in pancreatic ductal adenocarcinoma is somewhat controversial. Transcription factor PROX1 is a target of Wnt/beta-catenin signaling and it is involved in carcinogenesis through alterations in its expression. The actions can be either oncogenic or tumor suppressive depending on the tissue. The aim of this study was to investigate PROX1 and beta-catenin expression in pancreatic ductal adenocarcinoma (PDAC). Methods: Expression of PROX1 and beta-catenin were evaluated in 156 patients by immunohistochemistry of tissue microarrays. Associations between tumor marker expression and clinicopathological parameters were assessed by the Fischer's exact-test or the linear-by-linear association test. The Kaplan-Meier method and log-rank test were used for survival analysis. Uni- and multivariate survival analyses were carried out by the Cox regression proportional hazard model. Results: High PROX1 expression was seen in 74 (48 %) tumors, and high beta-catenin expression in 100 (65 %). High beta-catenin expression was associated with lower tumor grade (p = 0.025). High PROX1 and beta-catenin expression associated significantly with lower risk of death from PDAC in multivariate analysis (HR = 0.63; 95 % CI 0.42-0.95, p = 0.026; and HR = 0.54; 95 % CI 0.35-0.82, p = 0.004; respectively). The combined high expression of PROX1 and beta-catenin also predicted lower risk of death from PDAC (HR = 0.46; 95 % CI 0.28-0.76, p = 0.002). Conclusion: In conclusion, high PROX1 and beta-catenin expression were independent factors for better prognosis in pancreatic ductal adenocarcinoma.
Subject: Pancreatic ductal adenocarcinoma
Beta-catenin
PROX1
Prognosis
TRANSCRIPTION FACTOR
COLORECTAL-CANCER
E-CADHERIN
ALPHA-CATENIN
EXPRESSION
GENE
PROGRESSION
GROWTH
DIFFERENTIATION
DYSREGULATION
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
art_3A10.1186_2Fs12885_016_2497_5.pdf 2.783Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record